ClinicalTrials.gg
CompletedNCT00097916Updated Mar 5, 2012

An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease

A Phase 3 interventional study of memantine HCl in Alzheimer's Disease, sponsored by Forest Laboratories. Completed at 9 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2012-03-05.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing memantine in Alzheimer Disease — 1 open to participants now, 2 under way, none of them phase 3. Memantine · Alzheimer Disease.

Enrollment
25th of 34
34 · median 90
Started
2004
with 2 others
Phase 3
8 of 34
none open now
Registered
1st of 34
by date
Lead sponsor
4 of 34
Forest Laboratories

Among the 34 studies testing memantine in Alzheimer Disease, this one is the 25th largest by enrollment, is one of 3 that started in 2004, is one of 8 in phase 3, and was the 1st registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 34 studies testing memantine in Alzheimer Disease is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About memantine

Memantine: first FDA approval 2003 (NAMENDA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing memantine in Alzheimer Disease, or all of them as a file.
02

Study summary

About 65% of patients with severe Alzheimer's Disease (AD) will have symptoms of agitation. There are drawbacks associated with the currently available therapeutic interventions for agitation associated with Alzheimer's Disease. In a recent trial, in the group of patients with moderate to severe AD treated with memantine, there were fewer incidences of agitation. It is hypothesized that memantine will be effective in reducing the symptoms of agitation associated with moderate to severe Alzheimer's Disease.

03

Conditions studied

  • Alzheimer's Disease

Keywords

  • memantine HCl
  • Dementia
  • Agitation
  • Alzheimer Disease
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderate to Severe Alzheimer's Disease with a score greater than or equal to 4 on agitation/aggression domain of NPI
  • Stable dose of donepezil for 3 months

Exclusion criteria

Exclusion Criteria:

  • Other evidence of psychiatric disorders
  • Oncologic diagnosis
  • gastrointestinal, renal, hepatic, endocrine or cardiovascular disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
34 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Neuropsychiatric Inventory

Secondary outcomes

  1. Cohen Mansfield Agitation Inventory

  2. Clinical Global Impression Scale

  3. ADCS-ADL

  4. Agitation/aggression domain of Neuropsychiatric Inventory (NPI)

07

Study locations

9 sites
  • The Forves Norris MDA/ALS Research Center
    San Francisco, California 94115, United States
  • Coastal Communities Hospital
    Westminster, California 92683, United States
  • Alzheimer's Disease Research Unit
    New Haven, Connecticut 06510, United States
  • Berma Research Group
    Hialeah, Florida 33016, United States
  • Baumel-Eisner Neuromedical Institute
    Miami, Florida 33154, United States
  • Premiere Research Institute
    West Palm Beach, Florida 33407, United States
  • Geriatric Medicine
    Honolulu, Hawaii 96817, United States
  • The Memory Clinic
    Bennington, Vermont 05201, United States
  • Hampton Roads Center for Clinical Research
    Norfolk, Virginia 23502, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004, a primary completion of Apr 2006 and a completion of Apr 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2004
First posted
Dec 2, 2004
Start
Sep 2004
Primary completionActual
Apr 2006
CompletionActual
Apr 2006
Last update
Mar 5, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00097916
First posted
Dec 2, 2004
Start date
Sep 2004
Primary completion
Apr 2006
Completion
Apr 2006
Last update
Mar 5, 2012
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Memantine

Start the discussion